North Yorkshire & York Area Prescribing Committee

Summary of decisions made regarding new product requests considered at a meeting of the Committee on the 5th April 2023.

Classification of products:

G **Green drug** - Can be initiated and prescribed in all care settings O- Second line / alternative green drug

ASR **Amber Specialist Recommendation drug -** Can be recommended by a specialist for initiation in primary care

ASI **Amber Specialist Initiation drug** – Initiated by a specialist and transferred to primary care once the patient stabilised. In some cases there may be a further restriction for use outlined - these will be defined in each case.

ASC **Amber Shared Care drug** - These are specialist drugs which must be initiated by the specialist, but with the potential to transfer to primary care within written and agreed shared care protocols and according to the agreed process for transfer of care

R **Red drug** - Drugs that should remain under the total responsibility of the specialist. Usually considered as "hospital only" drugs

BLACK **Not Approved** - Drugs that have been considered by the APC or other approved body and are not approved for prescribing within North Yorkshire & York.

GREY **Not Reviewed** - Drugs that have not been reviewed by the APC yet. This usually means that no application has been received or that an application is in progress. These drugs are not normally considered appropriate for prescribing in North Yorkshire & York.

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
1) Requests deferred from previous meeting				
Nil				
2) New Requests				
Buprenorphine Long Acting Injection (Buvidal®)	✓ R			Requested for treatment of opioid dependence within a framework of medical, social and psychological treatment. Treatment is intended for use in adults and adolescents aged 16 years or over. **Decision:** approved as RED drug within service commissioned by North Yorkshire County Council as an alternative option for consideration to buprenorphine sublingual preparations and methadone oral solution in patients meeting the one of the following criteria: 1. travel abroad 2. have work or study commitments 3. have mobility issues 4. live in rural areas where access to community pharmacies providing substance misuse services will be difficult 5. have regular release from custody on license for short periods 6. have highly complex lifestyles, where diversion is probable and/or safe home storage is unlikely

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
Dexcom ONE Real-time Continuous Glucose Monitoring (rt-CGM)	✓ **ASR**			Requested as option in children & adults with Type 1 or Type 2 adults with diabetes on multiple daily insulin injections and including pregnant women, as outlined in NICE guidance https://www.nice.org.uk/guidance/ng28 https://www.nice.org.uk/guidance/ng17 https://www.nice.org.uk/guidance/ng18 https://www.nice.org.uk/guidance/ng3 **Decision:** approved as AMBER specialist recommendation for both type 1 and type 2 diabetes patients subject to ICB approval of the overall CGM policy and an educational programme being in place for primary care.
3) New formulations & extensions to use				
Nil this month				
5) Products considered by NICE				
TA871: Eptinezumab for preventing migraine	✓ **R**			The formulary will reflect the TAG – ICS is the responsible commissioner. 30-day NICE TA published 1st March 2023.
TA861: Upadacitinib for treating active non-radiographic axial spondyloarthritis	✓ **R**			Updated pathway approved at Feb 2023 APC as was a 30 day NICE TA
TA862: Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments	✓ **R**			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA863: Somatrogon for treating growth disturbance in children and young people aged 3 years and over	✓ **ASI in paeds**			The formulary will reflect the TAG – ICS is the responsible commissioner. 30-day NICE TA published 1st February 2023.
TA864: Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted	✓ **R**			The formulary will reflect the TAG – NHS England is the responsible commissioner.

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
TA865: Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA866: Regorafenib for previously treated metastatic colorectal cancer	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA867: Mitapivat for treating pyruvate kinase deficiency (terminated appraisal)				The formulary will reflect the TAG – NHS England is the responsible commissioner. Received for information.
TA868: Vutrisiran for treating hereditary transthyretin-related amyloidosis	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA869: Teclistamab for treating relapsed or refractory multiple myeloma after 3 or more therapies (terminated appraisal)				The formulary will reflect the TAG – NHS England is the responsible commissioner. Received for information.
TA870: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA872: Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
HST22: Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
6) Appeals against earlier decisions by the APC				
None				
7) Miscellaneous formulary decisions by the APC				
Freestyle Libre 2	✓ **ASR**			**Decision:** formulary status to change from AMBER SI to AMBER SR to match that of Dexcom ONE subject to ICB approval of the overall CGM policy and an educational programme being in place for primary care.

The following guidelines were presented to and approved at the April 2023 meeting of the APC:

- NY&Y APC Migraine pathway

The following guidelines were presented to and recommended for approval to the HNY IPMOC at the April 2023 meeting of the APC:

- Nil this month.

The following shared care guidelines were presented to and approved at the April 2023 meeting of the APC:

- Nil this month.

The following documents/guidelines were presented to the April 2023 meeting of the APC for comment:

- Guidelines for recognition and management of non- IgE cow's milk allergy in children – partial update